Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Oct, 2017 | Pages:
61 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) - Pipeline Review, H2 2017 Summary Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) - 11beta-hydroxysteroid dehydrogenase type 1 is an NADPH-dependent enzyme highly expressed in key metabolic tissues including liver, adipose tissue, and the central nervous system. In these tissues HSD11B1 reduces cortisone to the active hormone cortisol that activates glucocorticoid receptors. This enzyme plays an important role in obesity and insulin resistance. Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) pipeline Target constitutes close to 16 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 3, 1, 6 and 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively. Report covers products from therapy areas Metabolic Disorders, Central Nervous System, Ophthalmology, Cardiovascular, Dermatology and Immunology which include indications Type 2 Diabetes, Obesity, Alzheimer's Disease, Glaucoma, Cardiomyopathy, Cushing's Syndrome, Dementia Associated With Alzheimer's Disease, Inflammation, Intracranial Hypertension, Metabolic Syndrome, Ocular Hypertension, Open-Angle Glaucoma, Osteopenia, Psychiatric Disorders and Wounds. The latest report Corticosteroid 11 Beta Dehydrogenase Isozyme 1 - Pipeline Review, H2 2017, outlays comprehensive information on the Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) targeted therapeutics development with respective active and dormant or discontinued projects. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) - The report reviews Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) targeted therapeutics and enlists all their major and minor projects - The report assesses Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) - Overview 7 Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) - Therapeutics Development 8 Products under Development by Stage of Development 8 Products under Development by Therapy Area 9 Products under Development by Indication 10 Products under Development by Companies 11 Products under Development by Universities/Institutes 13 Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) - Therapeutics Assessment 15 Assessment by Mechanism of Action 15 Assessment by Route of Administration 16 Assessment by Molecule Type 18 Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) - Companies Involved in Therapeutics Development 19 Actinogen Medical Ltd 19 Astellas Pharma Inc 19 AstraZeneca Plc 20 Boehringer Ingelheim GmbH 20 Connexios Life Sciences Pvt Ltd 20 F. Hoffmann-La Roche Ltd 21 Hyundai Pharmaceutical Co Ltd 21 Laboratorios SALVAT SA 22 Poxel SA 22 SK Chemicals Co Ltd 23 Toray Industries Inc 23 Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) - Drug Profiles 24 ASP-3662 - Drug Profile 24 Product Description 24 Mechanism Of Action 24 R&D Progress 24 AZD-4017 - Drug Profile 25 Product Description 25 Mechanism Of Action 25 R&D Progress 25 BI-135558 - Drug Profile 27 Product Description 27 Mechanism Of Action 27 R&D Progress 27 CNX-1049 - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 Drugs to Inhibit 11beta-HSD1 for Wound Healing - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 HIS-388 - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 HOB-046 - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 KR-66344 - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 NCE-402 - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 RO-5093151 - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 Small Molecules to Inhibit 11 Beta Hydroxysteroid Dehydrogenase 1 for Metabolic Diseases - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 Small Molecules to Inhibit 11 Beta-Hydroxysteroid Dehydrogenase 1 for Type 2 Diabetes - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 SVT-63 - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 SVT-88 - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 TR-013A - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 UE-2343 - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) - Dormant Products 44 Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) - Discontinued Products 46 Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) - Product Development Milestones 47 Featured News & Press Releases 47 Sep 07, 2017: Actinogen Medical: First patient completes landmark Alzheimer's disease trial 47 Aug 16, 2017: First UK patient treated in ground-breaking Alzheimer's clinical trial 47 Jul 26, 2017: Actinogen Medical Provides Update on Xanamem 48 Jun 22, 2017: First US patients treated in landmark Alzheimers disease trial 50 Jun 01, 2017: First UK site goes live in global Alzheimer's disease clinical trial 51 May 16, 2017: First patient treated in landmark Alzheimer's disease clinical trial 51 Apr 26, 2017: Actinogen provides March quarterly update 52 Mar 08, 2017: TGA Regulatory Approval Received for Alzheimer's Phase II Trial 54 Feb 27, 2017: Actinogen announce Medical Half-Year Results 55 Feb 09, 2017: Xanamem research published in prestigious medical journal 56 Jan 10, 2017: UK Regulatory Approval for Alzheimer's Disease Clinical Trial - XanADu 57 Jan 03, 2017: FDA Approval to Commence Alzheimer's Disease Clinical Trial 58 Dec 19, 2016: Significant Advance In Development Of Actinogen Medical Alzheimer's Drug Xanamem 58 Dec 06, 2016: Actinogen Medical: Xanamem Research Presented At CTAD 59 Sep 29, 2016: FDA Feedback On Xanamem Alzheimers Trial 59 Appendix 60 Methodology 60 Coverage 60 Secondary Research 60 Primary Research 60 Expert Panel Validation 60 Contact Us 60 Disclaimer 61
List of Tables
Number of Products under Development by Stage of Development, H2 2017 8 Number of Products under Development by Therapy Areas, H2 2017 9 Number of Products under Development by Indication, H2 2017 10 Number of Products under Development by Companies, H2 2017 11 Products under Development by Companies, H2 2017 12 Number of Products under Investigation by Universities/Institutes, H2 2017 13 Products under Investigation by Universities/Institutes, H2 2017 14 Number of Products by Stage and Mechanism of Actions, H2 2017 15 Number of Products by Stage and Route of Administration, H2 2017 17 Number of Products by Stage and Molecule Type, H2 2017 18 Pipeline by Actinogen Medical Ltd, H2 2017 19 Pipeline by Astellas Pharma Inc, H2 2017 19 Pipeline by AstraZeneca Plc, H2 2017 20 Pipeline by Boehringer Ingelheim GmbH, H2 2017 20 Pipeline by Connexios Life Sciences Pvt Ltd, H2 2017 21 Pipeline by F. Hoffmann-La Roche Ltd, H2 2017 21 Pipeline by Hyundai Pharmaceutical Co Ltd, H2 2017 22 Pipeline by Laboratorios SALVAT SA, H2 2017 22 Pipeline by Poxel SA, H2 2017 23 Pipeline by SK Chemicals Co Ltd, H2 2017 23 Pipeline by Toray Industries Inc, H2 2017 23 Dormant Products, H2 2017 44 Dormant Products, H2 2017 (Contd..1), H2 2017 45 Discontinued Products, H2 2017 46
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
